A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor

Thumbnail Image

Files

a_matchingadjusted_indirect_c-20260716094909246231.pdf (569.45 KB)

Date issued

2025

Authors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

Reuse License

CC-BY-4.0
Description of rights: CC-BY-4.0
Item type: Item , ZeitschriftenaufsatzAccess status: Open Access ,

DOI

https://doi.org/10.25358/openscience-15655

Description

Keywords

Citation

URI

https://openscience.ub.uni-mainz.de/handle/20.500.12030/15676

Published in

British journal of haematology, 208, 1, Wiley, Oxford, 2025, https://doi.org/10.1111/bjh.70237

Relationships

Collections

DFG-491381577-H

Endorsement

Review

Supplemented By

Referenced By